87
Participants
Start Date
April 30, 2010
Primary Completion Date
June 30, 2015
Study Completion Date
November 30, 2015
Trivax, Temozolomide, Surgery, Radiotherapy
"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
Temozolomide, Surgery, Radiotherapy
"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
Neuroonkologisches Tumorboard KFJ-KA; Rudolfsstiftung, Vienna
Department of Paediatrics, Medical University Vienna, Vienna
Medical Department of Oncology, Donauspital, SMZ-Ost, Vienna
Landesnervenklinik Wagner-Jauregg, Linz
Department of Neurosurgery, Christian Doppler Klinik, Paracelsus Medizinische Privatuniversität, Salzburg
Clinical Department of Neurology, Medical University Innsbruck, Innsbruck
Landeskrankenhaus Feldkirch, Feldkirch
Department of Neurosurgery, Medical University Graz, Graz
Lead Sponsor
Activartis Biotech
INDUSTRY